# Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes

> **NCT01890122** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 647 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** Alogliptin
- **DRUG:** Metformin HCl
- **DRUG:** Alogliptin and Metformin Fixed-Dose Combination (FDC)
- **DRUG:** Alogliptin Placebo
- **DRUG:** Metformin Placebo
- **DRUG:** Alogliptin and Metformin FDC Placebo

## Key facts

- **NCT ID:** NCT01890122
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2015-09
- **Final completion:** 2015-10
- **Target enrollment:** 647 (ACTUAL)
- **Last updated:** 2016-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01890122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01890122, "Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01890122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*